Message Font: Serif | Sans-Serif
No. of Recommendations: 0
this should help my average in the contest (SLXP has done well but ARRY has dragged me down),

oh, and yes, it should help keep ARRY in business while they continue development

Amgen threw them $60M to get in on the diabetes development (and more)
Amgen will pay $60 million up front to Array. Amgen also will fund some full-time Array employees as part of a two-year research collaboration.

Amgen will receive exclusive worldwide rights to Array's small-molecule glucokinase activator program, aimed at developing drugs that help the body produce more insulin. That program includes a potential drug compound, ARRY-403, in early-stage testing. Amgen officials said the compound strengthens the company's diabetes pipeline.

Array also will receive royalties on sales of the drug and could earn additional payments based on clinical and commercial milestones, the companies said in a statement.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.